A Phase i clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy

Michael J. Pishvaian, Rebecca Slack, Eunice Y. Koh, Jan H. Beumer, Marion L. Hartley, Ion Cotarla, John Deeken, Aiwu Ruth He, Jimmy Hwang, Shakun Malik, Kashif Firozvi, Minetta C Liu, Beth Elston, Sandy Strychor, Merrill J. Egorin, John L. Marshall

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose Pre-clinical data suggest that combining imatinib with traditional cytotoxic chemotherapy may improve imatinib efficacy. We conducted a Phase I study of imatinib in combination with paclitaxel in patients with advanced or metastatic solid tumors. Methods Patients were accrued to the study in a standard 3 + 3 design. Patients were restaged every two cycles, and those with stable disease (SD), or better, continued study treatment without interruption. Maximally tolerated doses (MTDs) and pharmacokinetic profiles of combination imatinib and paclitaxel were assessed. Results Fifty-eight patients were enrolled, including 40 in the Phase I dose escalation portion. Alternating dose escalation of imatinib and paclitaxel on a 28-day cycle resulted in MTDs of 800 mg imatinib daily, on days 1-4, 8-11, 15-18, and 22-25, and 100 mg/m2 paclitaxel weekly, on days 3, 10, and 17. Two expansion cohorts, comprising 10 breast cancer patients and 8 patients with soft-tissue sarcomas, were enrolled at the MTDs. The most common adverse events were flu-like symptoms (64 %) and nausea/vomiting (71 %). The most common Grade 3/4 toxicities were neutropenia (26 %), flu-like symptoms (12 %), and pain (12 %). There were no relevant differences in the pharmacokinetic profiles of either drug when given in combination compared with alone. Thirty-eight subjects were evaluable for response, 18 (47.4 %) of whom experienced clinical benefit. Five patients (13.2 %) had a partial response (PR) and 13 patients (34.2 %) had SD; the average time to progression in those with clinical benefit was 17 weeks (range: 7-28 weeks). Conclusions This combination of imatinib and paclitaxel was reasonably safe and tolerable, and demonstrated evidence of anti-tumor activity. Further exploration in diseasespecific Phase II trials is warranted.

Original languageEnglish (US)
Pages (from-to)843-853
Number of pages11
JournalCancer Chemotherapy and Pharmacology
Volume70
Issue number6
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Paclitaxel
Refractory materials
Tumors
Clinical Trials
Maximum Tolerated Dose
Neoplasms
Pharmacokinetics
Therapeutics
Chemotherapy
Imatinib Mesylate
Neutropenia
Toxicity
Sarcoma
Nausea
Vomiting
Tissue
Breast Neoplasms
Drug Therapy
Pain
Pharmaceutical Preparations

Keywords

  • Imatinib
  • Paclitaxel
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

A Phase i clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. / Pishvaian, Michael J.; Slack, Rebecca; Koh, Eunice Y.; Beumer, Jan H.; Hartley, Marion L.; Cotarla, Ion; Deeken, John; He, Aiwu Ruth; Hwang, Jimmy; Malik, Shakun; Firozvi, Kashif; Liu, Minetta C; Elston, Beth; Strychor, Sandy; Egorin, Merrill J.; Marshall, John L.

In: Cancer Chemotherapy and Pharmacology, Vol. 70, No. 6, 12.2012, p. 843-853.

Research output: Contribution to journalArticle

Pishvaian, MJ, Slack, R, Koh, EY, Beumer, JH, Hartley, ML, Cotarla, I, Deeken, J, He, AR, Hwang, J, Malik, S, Firozvi, K, Liu, MC, Elston, B, Strychor, S, Egorin, MJ & Marshall, JL 2012, 'A Phase i clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy', Cancer Chemotherapy and Pharmacology, vol. 70, no. 6, pp. 843-853. https://doi.org/10.1007/s00280-012-1969-9
Pishvaian, Michael J. ; Slack, Rebecca ; Koh, Eunice Y. ; Beumer, Jan H. ; Hartley, Marion L. ; Cotarla, Ion ; Deeken, John ; He, Aiwu Ruth ; Hwang, Jimmy ; Malik, Shakun ; Firozvi, Kashif ; Liu, Minetta C ; Elston, Beth ; Strychor, Sandy ; Egorin, Merrill J. ; Marshall, John L. / A Phase i clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. In: Cancer Chemotherapy and Pharmacology. 2012 ; Vol. 70, No. 6. pp. 843-853.
@article{5df4480dacbe4578a9dbb633dc48e1c5,
title = "A Phase i clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy",
abstract = "Purpose Pre-clinical data suggest that combining imatinib with traditional cytotoxic chemotherapy may improve imatinib efficacy. We conducted a Phase I study of imatinib in combination with paclitaxel in patients with advanced or metastatic solid tumors. Methods Patients were accrued to the study in a standard 3 + 3 design. Patients were restaged every two cycles, and those with stable disease (SD), or better, continued study treatment without interruption. Maximally tolerated doses (MTDs) and pharmacokinetic profiles of combination imatinib and paclitaxel were assessed. Results Fifty-eight patients were enrolled, including 40 in the Phase I dose escalation portion. Alternating dose escalation of imatinib and paclitaxel on a 28-day cycle resulted in MTDs of 800 mg imatinib daily, on days 1-4, 8-11, 15-18, and 22-25, and 100 mg/m2 paclitaxel weekly, on days 3, 10, and 17. Two expansion cohorts, comprising 10 breast cancer patients and 8 patients with soft-tissue sarcomas, were enrolled at the MTDs. The most common adverse events were flu-like symptoms (64 {\%}) and nausea/vomiting (71 {\%}). The most common Grade 3/4 toxicities were neutropenia (26 {\%}), flu-like symptoms (12 {\%}), and pain (12 {\%}). There were no relevant differences in the pharmacokinetic profiles of either drug when given in combination compared with alone. Thirty-eight subjects were evaluable for response, 18 (47.4 {\%}) of whom experienced clinical benefit. Five patients (13.2 {\%}) had a partial response (PR) and 13 patients (34.2 {\%}) had SD; the average time to progression in those with clinical benefit was 17 weeks (range: 7-28 weeks). Conclusions This combination of imatinib and paclitaxel was reasonably safe and tolerable, and demonstrated evidence of anti-tumor activity. Further exploration in diseasespecific Phase II trials is warranted.",
keywords = "Imatinib, Paclitaxel, Phase I",
author = "Pishvaian, {Michael J.} and Rebecca Slack and Koh, {Eunice Y.} and Beumer, {Jan H.} and Hartley, {Marion L.} and Ion Cotarla and John Deeken and He, {Aiwu Ruth} and Jimmy Hwang and Shakun Malik and Kashif Firozvi and Liu, {Minetta C} and Beth Elston and Sandy Strychor and Egorin, {Merrill J.} and Marshall, {John L.}",
year = "2012",
month = "12",
doi = "10.1007/s00280-012-1969-9",
language = "English (US)",
volume = "70",
pages = "843--853",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - A Phase i clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy

AU - Pishvaian, Michael J.

AU - Slack, Rebecca

AU - Koh, Eunice Y.

AU - Beumer, Jan H.

AU - Hartley, Marion L.

AU - Cotarla, Ion

AU - Deeken, John

AU - He, Aiwu Ruth

AU - Hwang, Jimmy

AU - Malik, Shakun

AU - Firozvi, Kashif

AU - Liu, Minetta C

AU - Elston, Beth

AU - Strychor, Sandy

AU - Egorin, Merrill J.

AU - Marshall, John L.

PY - 2012/12

Y1 - 2012/12

N2 - Purpose Pre-clinical data suggest that combining imatinib with traditional cytotoxic chemotherapy may improve imatinib efficacy. We conducted a Phase I study of imatinib in combination with paclitaxel in patients with advanced or metastatic solid tumors. Methods Patients were accrued to the study in a standard 3 + 3 design. Patients were restaged every two cycles, and those with stable disease (SD), or better, continued study treatment without interruption. Maximally tolerated doses (MTDs) and pharmacokinetic profiles of combination imatinib and paclitaxel were assessed. Results Fifty-eight patients were enrolled, including 40 in the Phase I dose escalation portion. Alternating dose escalation of imatinib and paclitaxel on a 28-day cycle resulted in MTDs of 800 mg imatinib daily, on days 1-4, 8-11, 15-18, and 22-25, and 100 mg/m2 paclitaxel weekly, on days 3, 10, and 17. Two expansion cohorts, comprising 10 breast cancer patients and 8 patients with soft-tissue sarcomas, were enrolled at the MTDs. The most common adverse events were flu-like symptoms (64 %) and nausea/vomiting (71 %). The most common Grade 3/4 toxicities were neutropenia (26 %), flu-like symptoms (12 %), and pain (12 %). There were no relevant differences in the pharmacokinetic profiles of either drug when given in combination compared with alone. Thirty-eight subjects were evaluable for response, 18 (47.4 %) of whom experienced clinical benefit. Five patients (13.2 %) had a partial response (PR) and 13 patients (34.2 %) had SD; the average time to progression in those with clinical benefit was 17 weeks (range: 7-28 weeks). Conclusions This combination of imatinib and paclitaxel was reasonably safe and tolerable, and demonstrated evidence of anti-tumor activity. Further exploration in diseasespecific Phase II trials is warranted.

AB - Purpose Pre-clinical data suggest that combining imatinib with traditional cytotoxic chemotherapy may improve imatinib efficacy. We conducted a Phase I study of imatinib in combination with paclitaxel in patients with advanced or metastatic solid tumors. Methods Patients were accrued to the study in a standard 3 + 3 design. Patients were restaged every two cycles, and those with stable disease (SD), or better, continued study treatment without interruption. Maximally tolerated doses (MTDs) and pharmacokinetic profiles of combination imatinib and paclitaxel were assessed. Results Fifty-eight patients were enrolled, including 40 in the Phase I dose escalation portion. Alternating dose escalation of imatinib and paclitaxel on a 28-day cycle resulted in MTDs of 800 mg imatinib daily, on days 1-4, 8-11, 15-18, and 22-25, and 100 mg/m2 paclitaxel weekly, on days 3, 10, and 17. Two expansion cohorts, comprising 10 breast cancer patients and 8 patients with soft-tissue sarcomas, were enrolled at the MTDs. The most common adverse events were flu-like symptoms (64 %) and nausea/vomiting (71 %). The most common Grade 3/4 toxicities were neutropenia (26 %), flu-like symptoms (12 %), and pain (12 %). There were no relevant differences in the pharmacokinetic profiles of either drug when given in combination compared with alone. Thirty-eight subjects were evaluable for response, 18 (47.4 %) of whom experienced clinical benefit. Five patients (13.2 %) had a partial response (PR) and 13 patients (34.2 %) had SD; the average time to progression in those with clinical benefit was 17 weeks (range: 7-28 weeks). Conclusions This combination of imatinib and paclitaxel was reasonably safe and tolerable, and demonstrated evidence of anti-tumor activity. Further exploration in diseasespecific Phase II trials is warranted.

KW - Imatinib

KW - Paclitaxel

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=84871200729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871200729&partnerID=8YFLogxK

U2 - 10.1007/s00280-012-1969-9

DO - 10.1007/s00280-012-1969-9

M3 - Article

C2 - 23014737

AN - SCOPUS:84871200729

VL - 70

SP - 843

EP - 853

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -